A bstract. To determine the mechanism and the site of action of catecholamines as well as hormones including thyrotropin-releasing hormone (TRH)' and somatostatin on pituitary hormone release in patients with acromegaly and in normal subjects, the effects of these substances on growth hormone (GH) and prolactin (PRL) secretion from adenomatous and nonadenomatous human pituitary cells in culture were examined. When dopamine (0.01-0.1 tM) or bromocriptine (0.01-0.1 tM) was added to the culture media, a significant inhibition of GH 
A bstract. To determine the mechanism and the site of action of catecholamines as well as hormones including thyrotropin-releasing hormone (TRH)' and somatostatin on pituitary hormone release in patients with acromegaly and in normal subjects, the effects of these substances on growth hormone (GH) and prolactin (PRL) secretion from adenomatous and nonadenomatous human pituitary cells in culture were examined. When dopamine (0.01-0.1 tM) or bromocriptine (0.01-0.1 tM) was added to the culture media, a significant inhibition of GH and PRL secretion from adenoma cells from acromegalic patients was observed. This inhibition was blocked by D2 receptor blockade with metoclopramide or sulpiride, but not by DI receptor blockade. Similarly, dopamine suppressed GH and PRL release by nonadenomatous pituitary cells in a dose-dependent manner, which was again blocked by D2 receptor blockade. The minimum effective concentration of dopamine required for a significant inhibition of PRL secretion (0.01 tM) was lower than that for GH release (0.1 sM). Norepinephrine, likewise, caused a suppression ofPRL secretion from adenomatous and nonadenomatous pituitary cells. This effect was blocked by sulpiride, phentolamine, however, was ineffective. When secretion to various stimuli in acromegalic patients have been well documented. Administration of dopaminergic agonists to normal men results in an elevation of the circulating levels of GH (1) (2) (3) (4) . In contrast, the same maneuver has been shown to decrease serum GH levels in most, though not all, patients with acromegaly (3, (5) (6) (7) (8) . On the basis ofthis finding, bromocriptine, a dopaminergic agonist with a prolonged action, has been successfully introduced into the medical management of this disorder (9) (10) (11) (12) .
We have previously shown, using an in vitro perfusion technique, that dopaminergic agonist does inhibit GH and prolactin (PRL) secretion from perfused pituitary adenoma tissues of acromegalic patients (13) . This finding was subsequently confirmed by other investigators (14) (15) (16) (17) (18) . We have also demonstrated by this experimental approach that thyrotropin-releasing hormone These results indicate that dopaminergic agonists and TRH affect GH and PRL secretion in these patients by their direct action on pituitary adenoma, and further suggest that a possible alteration in cellular membrane receptors of the pituitary adenoma of acromegalic patients may be responsible for anomalous GH responses. Of importance in this regard is the fact that the in vitro responses of normal human pituitaries to these stimuli are not well established. Moreover, a number of substances, in addition to dopaminergic agonists and TRH, has been shown to affect GH and PRL secretion in acromegalic subjects, which includes adrenergic (21, 22) and serotoninergic antagonists (23, 24) . The present study was undertaken to examine the effects of these substances on GH and PRL secretion from pituitary adenoma cells of acromegaly at the cellular level using monolayer tissue culture, and to correlate them with the responses of nonadenomatous human pituitary cells in culture.
Methods
Subjects. 11 of time under the atmosphere of 95% air and 5% CO2. At the end of the incubation, the medium was removed and the cells were washed with 0.9% saline followed by extraction.
Extraction and immunoprecipitation of GH were conducted according to the general method described by Mains and Eipper (26) for adrenocorticotropic hormone with a modification (27) . Cells were frozen and thawed several times on dry ice and homogenized in 0.6 ml of 0.01 N NaOH (28) with a Teflon pestle. Extracts were titrated to pH 7.5 with 1 N HC1 and centrifuged at 2,300 g for 15 min at 4°C. An aliquot (10 Ad) of the supernate was incubated at 4°C with a sufficient amount (0.5 gl) of a specific rabbit anti-human (h)GH serum or nonimmune rabbit serum in the presence of 40 ,AI of 0.5% bovine serum albumin/ 0.1 M borate buffer (pH 8.6). This antiserum was generously provided by Dr. H. Demura of Tokyo Womens' Medical College. After 24 h of incubation, anti-rabbit IgG was added in an amount that maximally precipitated the rabbit IgG and incubation was continued overnight. Tubes were then centrifuged, and the immunoprecipitates of cell extracts were washed once in 2 ml of 0.05 M phosphate buffer containing 5 mM Na2EDTA and 0.25% Triton X-100 (pH 7.6) and once in 2 ml of 0.01 M phosphate buffer containing 15 mM NaCl (pH 7.2). The immune complex was dissolved by incubation in 0.2 ml of NCS tissue solubilizer (Amersham Corp., Arlington Heights, IL) and counted in a liquid scintillation spectrometer with 10 ml of scintillation fluid containing 6 g PPO and 0.1 g POPOP/liter of toluene.
Incubation of cells with test substances. Incubation studies were started after the cells formed a monolayer and performed at an interval of at least 2 d. Individual cultures were randomly allocated for each experiment. Four or more cultures were used for the control and variables, and run simultaneously.
On the day of experiment, the medium was replaced by 2 ml of Eagle's minimum essential medium in Earle's solution containing 0.5% human serum albumin instead of fetal calf serum. Cells were incubated for I h at 370C in a humidified atmosphere of 95% air and 5% CO2.
The medium was then removed and cells were further incubated for 2 h in 2 ml of fresh medium with or without the following substances: dopamine hydrochloride, L-3,4-dihydroxyphenylalanine (L-dopa), bromocriptine mesylate, haloperidol, metoclopramide, sulpiride, pimozide, YM-09 151-2 (Yamanouchi Pharmaceutical Co., Tokyo, Japan) (29), norepinephrine, phentolamine mesylate, TRH, somatostatin (Protein Research Foundation, Osaka, Japan), a-endorphin (Peninsula Laboratories, Inc., Belmont, CA), (3-endorphin (Peninsula Laboratories, Inc.), and methionine enkephalin (Calbiochem-Behring Corp., American Hoechtst Corp., San Diego, CA) In general, fresh solutions of these substances were prepared before each experiment by dissolving them directly in the incubation medium, with a few exceptions. Bromocriptine mesylate and haloperidol were first solubilized in glacial acetic acid and then diluted to a concentration of 10 mg/ml with distilled water. These stock solutions were serially diluted to an appropriate concentration with 0.9% saline and then with the incubation medium. YM-09151-2 was initially dissolved in 0.01 N HCl at a concentration of 1 mg/ml followed by dilution with 0.9% saline and the incubation medium. Dopamine, norepinephrine, and L-dopa were dissolved immediately before the experiment in the incubation medium, which contained ascorbic acid at the final concentration of0.1 mM. Control dishes received vehicle alone. When the combined effect of two test substances on hormone release was examined, they were added simultaneously to the incubation media. After incubation, the medium was centrifuged at 150 g for 10 min, and the supernate was stored at -20°C until analyzed.
Radioimmunoassays. GH and PRL concentrations in the medium of both preincubation and experimental incubation were determined by radioimmunoassays, as previously described in detail (7, 30 (Fig. 2 B) Fig. 3 . In all of the experiments, both GH and PRL secretion were inhibited by dopamine and, in addition, a dose-response relationship was observed between the dopamine concentrations and the amounts of hormones secreted into the media. The minimum effective concentration of dopamine required for a significant inhibition of PRL release (0.01 M) was lower than that for GH secretion (0.1 sM).
When dopamine at a concentration of 0.01 or 0.1 M was added to the incubation media, both GH and PRL release were significantly suppressed in adenoma cells of acromegaly. This -1 1, Fig. 5) .
In an attempt to determine whether L-dopa, which is known to lower serum GH levels of some acromegalic patients (5), may act on pituitary adenomas to affect GH secretion, the direct effect of L-dopa was studied using three different adenoma cells of acromegaly in culture. L-Dopa at a concentration of 0.1 guM showed little effect, although the equimolar concentration of dopamine significantly inhibited both GH and PRL secretion in all of the experiments (Figs. 4 and 5) . In one experiment, PRL secretion showed a slight but a significant reduction in response to this dose of L-dopa.
The effect of dopamine on GH and PRL secretion from nonadenomatous pituitary cells is shown in Fig. 6 . The addition of 0.1 gAM dopamine to the culture media induced a significant inhibition ofGH release in all ofthe three experiments conducted on different nonadenomatous somatotrophs. This inhibitory effect of dopamine on GH secretion observed in nonadenomatous GH cells was abolished by coincubation with an equimolar concentration of haloperidol. Similarly, sulpiride competed with the inhibitory action of dopamine on GH release (N2, Fig. 6 Effect of TRH on GH and PRL secretion from cultured pituitary cells. The addition of TRH to the incubation media significantly stimulated both GH and PRL secretion from cultured adenoma cells of acromegalic patients (Fig. 8) . Furthermore, a dose-response relationship was obtained between the concentrations of TRH added and the amounts of hormones secreted into the media. This stimulatory effect of TRH on GH secretion was most clearly demonstrated in the adenoma cells of acromegaly obtained from patient 3, in whom TRH induced a marked elevation of plasma GH levels (Table I) . Similarly, TRH at a concentration of0.1 M significantly stimulated PRL secretion from nonadenomatous pituitary cells in culture (N4, Fig. 8 ). TRH failed to enhance GH release from nonadenomatous somatotrophs in this experiment.
To study the interaction between the stimulatory effect of TRH and the inhibitory effect of dopaminergic agents, cultured adenoma cells from acromegalic patients were coincubated with TRH and dopamine. As shown in Fig. 9 , dopamine at a concentration of 0.1 or 0.01 tM significantly suppressed both GH and PRL release, whereas the addition of 0.1 or 0.01 EM TRH to the incubation media resulted in a significant increase in GH and PRL secretion. When cells were incubated with dopamine in the presence of an equimolar concentration of TRH, the inhibitory effect ofdopamine was overcome in two experiments (No. 3 and 6, Fig. 9 ). In the remaining one experiment, the effect of dopamine was not reversed by the addition of an equimolar concentration of TRH (No. 1, Fig. 9 ). When cells were incubated with bromocriptine instead of dopamine in three experiments, the doses of TRH required for the reversal of the inhibitory effect of bromocriptine were different from tissue to tissue and, in general, a higher dose of TRH was necessary.
Effect ofsomatostatin on GH and PRL secretion from cultured pituitary cells. Fig. 10 which was in good agreement with the in vivo GH response to TRH in this patient (Table I) . Further increase in TRH concentration (1 jiM) did not reverse the inhibitory effect of somatostatin on both GH and PRL (No. 1, Fig. 10 ). at a concentration of 0.1 LMM exerted an inhibitory action on both GH and PRL secretion (N2, Fig. 10 ). The magnitude of suppression by somatostatin was more pronounced in GH secretion than in PRL release, contrary to the inhibitory effect of dopamine on hormone secretion. secretion, on the other hand, was not consistently observed, although norepinephrine (1 gM) significantly inhibited GH release in some experiments, which was blocked by the D2 receptor blockade. It was concluded that the action of catecholamines on GH and PRL secretion from adenoma cells of acromegaly and nonadenomatous pituitary cells is mainly mediated through a dopaminergic mechanism. In adenoma cells of acromegaly, TRH stimulated both GH and PRL secretion, while it did only the latter in nonadenomatous pituitary cells in one experiment. This is consistent with the in vivo observation that TRH does not exhibit any effect on GH secretion in healthy subjects. Somatostatin, on the other hand, inhibited GH and PRL secretion in adenoma cells of acromegaly as well as in nonadenomatous pituitary cells in culture. Although it is now well established that somatostatin suppresses the circulating levels of GH in normal men and in patients with acromegaly (43) (44) (45) , its effect on PRL is controversial. Somatostatin may reduce plasma PRL levels in some, but not all, acromegalic patients, whereas plasma PRL concentrations are generally unaffected by somatostatin in healthy individuals. The discrepancy between in vivo and in vitro responses to somatostatin in normal subjects may be explained in part by the fact that nonadenomatous lactotrophs are less sensitive to somatostatin than somatotrophs as demonstrated in the present study and in part by the assumption that somatostatin may be more rapidly degraded in the circulation than in the incubation media.
When dopamine and TRH were coincubated, the response of GH secretion from adenoma cells of acromegaly was variable. In contrast, the stimulatory effect of TRH was unequivocally blocked by somatostatin even when a 10-fold higher concentration of TRH was used. These results, along with a difference in the sensitivity of GH and PRL cells to two substances alluded to above, suggest that there may exist a difference in the mode of the inhibitory action on hormone release between dopamine and somatostatin.
Although it has been recently shown that opioid peptides elevate the circulating levels of GH and PRL in man and in experimental animals (46) (47) (48) (49) (50) , there is a controversy regarding the mechanism ofaction ofopioid peptides to stimulate hormone release. In rat pituitaries, opioid peptides were found to counteract the inhibitory effect of dopamine on PRL secretion in vitro (51). However, opioid peptides alone or in combination with dopamine were completely inert in stimulation of PRL secretion from both adenomatous and nonadenomatous lactotrophs in the present study, which may agree with the ob-
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M. Ishibashi and T. Yamaji servation that the inhibition of PRL secretion induced by dopamine was not overcome by opioid peptides in perfused rat pituitaries (52) . The result may support the view that in man the site of action of opioid peptides on GH and PRL secretion may be the hypothalamus or higher central nervous system.
